SelSA

SelSA is a selective, orally active inhibitor for histone deacetylase 6 (HDAC6) with IC50 of 56.9 nM. SelSA inhibits the phosphorylation of ERK1/2. SelSA inhibits the proliferation of breast cancer cells and hepatocellular carcinoma cells with IC50 of 0.58-2.6 μM, inhibits cell migration and invasion of Huh7, and induces apoptosis. SelSA exhibits antitumor activity in mouse model[1][2].

Product Specifications

CAS Number

[1225038-92-5]

UNSPSC

12352005

Target

Apoptosis; HDAC

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/selsa.html

Purity

99.83

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

N#C[Se]CCCCCC(NC1=CC=CC=C1)=O

Molecular Formula

C13H16N2OSe

Molecular Weight

295.24

References & Citations

[1]Yang Z, et al. Histone Deacetylase 6 Inhibitor 5-Phenylcarbamoylpentyl Selenocyanide (SelSA) Suppresses Hepatocellular Carcinoma by Downregulating Phosphorylation of the Extracellular Signal-Regulated Kinase 1/2 Pathway[J]. ACS Pharmacology & Translational Science, 2024.|[2]Tang C, et al. A selenium-containing selective histone deacetylase 6 inhibitor for targeted in vivo breast tumor imaging and therapy[J]. Journal of Materials Chemistry B, 2019, 7 (22) : 3528-3536.